This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NOG · Western blot design guide
NOG Western Blot Planning Guide
Plan a NOG Western blot around the catalog-observed 25.8 kDa band, image-backed A04448-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
NOG Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 25.8 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Endometrium | |
| Negative control | Liver |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 25.8 kDa |
| ⓘ | Localization | Secreted |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated NOG Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Endometrium |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A04448-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected NOG Western Blot Band Size?
Use the product-observed 25.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 25.8 kDa | Matches the authoritative product WB observation. |
| 25.8 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected NOG appearancePlan around 25.8 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 25.8 kDa; use this as the primary experimental expectation. |
| Calculated mass | 25.8 kDa from UniProt Q13253; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A04448-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 25.8 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing NOG band
A04448-1 · NOG
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NOG Western blot
🧪Use Endometrium as the first positive-control candidate and Liver as the HPA Not detected negative candidate.
Positive control: Endometrium (High)
Negative control: Liver (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for NOG
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Endometrium | Reported tissue cells | High | Protein (HPA) | HPA → |
| Placenta | Reported tissue cells | High | Protein (HPA) | HPA → |
| Esophagus | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Lung | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced NOG Western Blot Tips
Deeper troubleshooting and optimisation questions for NOG, answered from its protein features.
Which band should guide the blot?
Use 25.8 kDa, the observation attached to the authoritative A04448-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 25.8 kDa expectation.
Which positive control should I start with?
Start with Endometrium, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Liver as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for NOG Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A04448-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC9756505, PMC12357823, PMC3329551.
Boster reagents
NOG Western Blot Reagents
Human-reactive NOG Western blot reagents with authoritative product imagery.
Real WB data
Anti-Noggin Antibody Picoband®
Cat # A04448-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q13253
- Human Protein Atlas — NOG
- A04448-1 product record
- PMC9756505 — Stage-specific requirement for METTL3-dependent m(6)A modification during dental pulp stem cell differentiation.
- PMC12357823 — A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer.
- PMC3329551 — Functional analysis of alleged NOGGIN mutation G92E disproves its pathogenic relevance.